Dr. Jack West reviews the implications, both encouraging and potentially detrimental, of a recent FDA approval for broad genomic (NGS) testing of all solid tumors, ushering in a new era of growing precision medicine and molecular oncology.
Genomic Sequencing for All Solid Tumors: Where Will This Lead Us? (BMIC-019)
